

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/668,248
				Filing Date	September 24, 2003
				First Named Inventor	WEBER, Eckard
				Art Unit	1655
				Examiner Name	Winston, Randall O.
Sheet	1	of	1	Attorney Docket Number	2009.0010005/RWE/RAS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	HELLSTROM, W.J.G., <i>et al.</i> , "Effects of Alprostadil and Prazosin on Motility, Viability and Membrane Integrity of Human Sperm," <i>J. Urol.</i> 159:1559-1562, American Urological Association, Inc. (1998)	
	NPL2	ROBINSON, C.P., and BITTLE, I., "Vascular Effects of Demethylchlordimeform, a Metabolite of Chlordimeform," <i>Pest. Biochem. Physiol.</i> 11:46-55, Academic Press, Inc. (1979)	
	NPL3	Database WPI, Accession No. 1991-203975, English language abstract for JP 3-128332 (listed as document FP2 on accompanying PTO/SB/08A)	
	NPL4	Database WPI, Accession No. 1995-379974, English language abstract for JP 7-258068 (listed as document FP4 on accompanying PTO/SB/08A)	
	NPL5	European Search Report for European Application No. EP 06 02 4671, Munich, Germany, completed on September 18, 2007	

747500_1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.